Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOODMAN: Denosumab Effects on Glucolipid, Cardiometabolic and Bone Metabolism in Men with Osteoporosis
ChiCTR2500112891Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis and osteopenia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Bone Mineral Density (BMD) and Bone Turnover Markers (BTMs). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on ChiCTR2500112891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112891.